OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
M&A Transactions
M&A Transaction Chart
Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.
Week ended 10/24/2025
Week ended 10/24/2025
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
M&A Transactions Commentary
Week ended 10/24/2025
- The Week’s Closed M&A Transactions:
- On October 18, 2025, AbbVie (ABBV: NYSE), a research-based biopharmaceutical company, closed on its acquisition of Gigamesh Pharmaceuticals’ Bretisilocin, a Phase 2 clinical development candidate for the treatment of patients with moderate to severe major depressive disorder.
- Abbvie paid approximately $1.2B for the asset, a relatively immaterial sum given the Pharmaceutical giant’s $406B market cap.
Week ended 10/24/2025
This is the MA basic
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.